{"entity":{"id":"engeneic","kind":"company","name":"EnGeneIC","aka":["EnGeneIC Ltd"],"tldr":"EnGeneIC is an Australian biotech that loads bacterially derived nanocells with chemotherapy and steers them to tumours with antibodies; E-EDV-D682 carries a super-cytotoxic payload to EGFR-expressing cancers.","summary":"EnGeneIC developed the EnGeneIC Dream Vector (EDV), a 400-nanometre bacterially derived minicell that is packed with a drug and coated with a bispecific antibody so it binds a tumour antigen and is taken up by the cancer cell. The EDVs also stimulate innate immunity. E-EDV-D682 targets EGFR and carries the PNU-159682 payload; it is being tested in pancreatic cancer and other advanced solid tumours, in some studies with immunomodulatory EDVs.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.engeneic.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["e-edv-d682"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Sydney","country":"AU","companyType":"biotech","website":"https://www.engeneic.com/","founded":2001,"investors":[],"funding":[]},"route":"/companies/engeneic/","neighbours":{"drug":[{"id":"e-edv-d682","kind":"drug","name":"E-EDV-D682","route":"/drugs/e-edv-d682/"}]}}